Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down

The New Role of Academia in Drug Discovery and Development: New Thinking, New Competencies, New Results
Bookmark and Share

Kauffman Foundation

Five leaders in the medical innovation field released a white paper today titled The New Role of Academia in Drug Discovery and Development: New Thinking, New Competencies, New Results. This white paper reflects key recommendations from a July 2010 town hall meeting in Kansas City hosted by Friends of Cancer Research, Kansas Bioscience Authority, The University of Kansas Cancer Center, Ewing Marion Kauffman Foundation and Council for American Medical Innovation.

The white paper outlines how government, nonprofit organizations and academic institutions can define new models of working with the private sector to enhance drug development efforts and bring safer, more effective drugs to the market more efficiently. Recommendations for this new model are based on a series of expert panel discussions held during the town hall meeting.
"This call to action is the result of an extraordinary meeting of key policy makers, academics, industry leaders and the non-profit community, who understand the urgency for new collaborations in cancer research and drug development," said Roy A. Jensen, M.D., director of The University of Kansas Cancer Center. "As universities increasingly seek to commercialize their research, we need a new paradigm for drug discovery. The University of Kansas Cancer Center is proud to partner with these organizations to lead the way."

"Together, we can knock down barriers to scientific innovation, and, as we do that, we will accelerate our progress in the fight against diseases such as cancer," said Tom Thornton, president and CEO of the Kansas Bioscience Authority.

"We hope our nation's healthcare leaders and policymakers will study the insights and adopt the recommendations in this report. We can make groundbreaking progress in how scientific discoveries translate to patient healthcare if they do," said Lesa Mitchell, vice president of advancing innovation at the Kauffman Foundation.

"This white paper outlines critical steps toward much-needed increased interagency collaboration," said Dr. Ellen Sigal, Chair, Friends of Cancer Research. "The proposals discussed within this document aim to accelerate the process to help get scientific breakthroughs to patients. The message is clear; without collaboration among all agencies and academic centers, the full potential of biomedical research may be stifled."

"The Council for American Medical Innovation is pleased to have supported this ground breaking event examining the new role of academia in drug development," said Debra Lappin, President of the Council for American Medical Innovation. "The white paper reflects a rare dialogue among leaders across sectors and paves the way forward for the next generation of research, discovery and medical advances."

Further Information


SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!